8-K: Microbot's LIBERTY System First Adopted by Emory Hospital

Microbot Medical announced Emory University Hospital is the first in the world to adopt its LIBERTY Endovascular Robotic System for patient care, marking a significant commercial milestone.

Summary

• Microbot Medical Inc. announced that Emory University Hospital in Atlanta has become the first hospital globally to adopt its LIBERTY Endovascular Robotic System for patient care.
• The Company is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology.
• LIBERTY is the only FDA cleared, single-use, remotely operated robotic system designed for peripheral endovascular procedures, aiming to reduce radiation exposure and physical strain.
• The system supports procedures such as liver tumor embolization, prostate artery embolization, and uterine fibroid embolization.
• Microbot commenced a limited market release weeks prior to this announcement and plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026.

Sentiment

Score: 8

Explanation: The announcement of the first hospital adoption of a key product, especially by a prestigious institution like Emory, is a very strong positive signal for the company's commercialization efforts and future prospects. The FDA clearance and unique features of the system further enhance this positive sentiment, despite the early stage of market release.

Positives

• Emory University Hospital is the first in the world to adopt the LIBERTY Endovascular Robotic System for patient care.
• Collaboration with Emory to establish an Endovascular Robotics Program enhances the growing field of interventional radiology.
• LIBERTY is FDA cleared, indicating regulatory approval for its use.
• The system is single-use and remotely operated, offering practical and scalable benefits.
• LIBERTY is designed to provide precise vascular navigation while aiming to reduce radiation exposure and physical strain for clinicians.
• The adoption by a nationally recognized academic medical center like Emory validates the technology and its potential.

Risks

• Market conditions may impact commercialization.
• Risks inherent in the commercialization of the LIBERTY Endovascular Robotic System and the development of future versions or applications.
• Uncertainty in the results of regulatory pathways and approvals.
• Uncertainty resulting from political, social, and geopolitical conditions, including changes in personnel or processes at the FDA.
• Disruptions from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries.
• Challenges in the maintenance of intellectual property rights.

Future Outlook

The Company plans for a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, with the goal to deepen market adoption. Management believes this adoption establishes a new medical robotic category.

Management Comments

• "Introducing innovative technologies such as LIBERTY to our interventional radiology program underscores our priority to remain at the forefront of technological advancement. We anticipate that its single-use, remotely operated design will offer a practical and scalable approach to robotics that supports our operational goals, protects our clinicians and provides access to quality care." J. David Prologo, MD, Division Director for Interventional Radiology, Emory University School of Medicine.
• "This is an extraordinary occasion for Microbot Medical, and we believe a major milestone for the entire surgical robotic space. We are establishing a completely new medical robotic category with the adoption of the first FDA-cleared single-use robotic system. This achievement reflects years of dedication and sustained progress by the entire team." Harel Gadot, CEO, President & Chairman.
• "We are proud to welcome them as the first adopter of LIBERTY, and we are committed to supporting them every step of the way to ensure clinical and operational success." Harel Gadot.

Industry Context

This announcement positions Microbot Medical at the forefront of the rapidly evolving interventional radiology and robotic surgery fields. The adoption of a single-use, remotely operated system like LIBERTY could set a new standard for efficiency and safety, potentially influencing broader trends in MedTech towards less invasive and more precise procedures. The collaboration with a leading academic medical center like Emory also highlights the growing importance of institutional partnerships in validating and advancing new medical technologies.

Stakeholder Impact

• Shareholders: Positive impact due to significant commercial milestone and validation of the company's core product, potentially leading to increased investor confidence.
• Clinicians (Emory): Enhanced capabilities for precise vascular navigation, reduced radiation exposure, and decreased physical strain during procedures.
• Patients (Emory): Access to advanced, precise, and potentially safer endovascular care.
• Company (Microbot Medical): Strengthened market position, enhanced credibility, and a clear path towards broader commercialization and market adoption.

Next Steps

• Full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026.
• Deepening market adoption of the LIBERTY system.
• Microbot Medical's commitment to supporting Emory University Hospital for clinical and operational success.

Key Dates

Recommendation

While the first adoption of the LIBERTY system by Emory University Hospital is a significant positive milestone and a strong validation of Microbot Medical's technology, it represents an early stage in the commercialization process. The full market release is still several months away, and widespread adoption and financial impact are yet to be demonstrated. Investors should monitor future sales figures, broader market acceptance, and the company's financial performance before making a definitive 'buy' decision. The current news warrants a 'hold' as it confirms progress but doesn't yet provide sufficient data for a strong long-term conviction without further developments.

Keywords

Microbot Medical, MBOT, LIBERTY System, Endovascular Robotics, Medical Devices, Robotic Surgery, Interventional Radiology, FDA Cleared, Emory University Hospital, Healthcare Technology, MedTech, Peripheral Procedures